ⓒ 2020-2024 Sana Biotechnology. All rights reserved
Our Pipeline
Changing the possible for patients
We never lose sight of why our work matters – the potential to impact the lives of patients is important to everyone at Sana. We are advancing a number of innovative drug candidates with the goal of disrupting the possible for patients across a diverse set of diseases.
Pipeline
The most advanced programs include an allogeneic CAR T program targeting CD19+ cancers (SC291), an allogeneic CAR T program for autoimmune diseases (SC291), an allogeneic CAR T program targeting CD22+ cancers (SC262), and a stem cell-derived pancreatic islet cell program for persons with type 1 diabetes (SC451). Our expanded access policy for access to our medicines in clinical trials can be found .
Ex Vivo Cell Engineering
Hypoimmune Technology: Donor-derived
Product CandidateCell TypePotential Indications
SC291 (CD19)
T cells
Oncology
Non-Hodgkin lymphoma (NHL)
Chronic lymphocytic leukemia (CLL)
Phase 1
ARDENT is a Phase 1 study evaluating SC291, a hypoimmune allogeneic CD19-directed CAR T cell therapy, for relapsed and/or refractory (r/r) B-cell malignancies.
SC291 (CD19)
T cells
Autoimmune Diseases
Lupus nephritis
Extrarenal SLE
ANCA-associated vasculitis (AAV)
Phase 1
GLEAMis a Phase 1 study evaluating SC291, a hypoimmune allogeneic CD19-directed CAR T cell therapy, for severe r/r B-cell mediated autoimmune diseases.
SC262 (CD22)
T cells
Oncology
Non-Hodgkin lymphoma (NHL)
Acute lymphoblastic leukemia (ALL)
Chronic lymphocytic leukemia (CLL)
Phase 1
VIVID is a Phase 1 study evaluating SC262, a hypoimmune allogeneic CD22-directed CAR T cell therapy, for r/r B-cell malignancies.
SC255 (BCMA)
T cells
Oncology
Multiple myeloma
Pre Clinical
Hypoimmune Technology: Stem cell-derived
Product CandidateCell TypePotential Indications
UP421
Investigator sponsored trial
Primary islet cells
Diabetes
Type 1 diabetes
IST
This is a first-in-human safety study of hypoimmune pancreatic islet cell transplantation for type 1 diabetes.
SC451
Islet cells
Diabetes
Type 1 diabetes
Pre Clinical
Stem cell-derived (to migrate to Hypoimmune Technology)
Product CandidateCell TypePotential Indications
SC379
Glial progenitor cells
Central nervous system (CNS)
Huntington’s disease
Pelizaeus-Merzbacher disease
Secondary progressive multiple sclerosis
Pre Clinical
Expanded Access Policy
Sana is committed to developing safe and effective engineered cells as medicines, which involves evaluation in clinical trials followed by submission of the trial results to regulatory agencies, such as the U.S. Food and Drug Administration (FDA). These investigational therapies have not yet been approved by regulatory authorities. “Expanded access” refers to the use of an unapproved investigational therapy outside of a clinical trial for the potential treatment of a serious or immediately life-threatening condition. We recognize that people living with the diseases we are studying may be interested in accessing our therapies prior to regulatory approval. We want to facilitate a comprehensive understanding of the safety, tolerability, and efficacy of our investigational therapies, which is why monitored participation in clinical trials is the only way to access our investigational therapies.
If you have additional questions, please speak with your physician.
Our therapies are investigational and have not been approved by the FDA or any other regulatory agency.
We use cookies to improve your experience on our website. By continuing to use this website, you agree to the use of cookies. To learn more about how we use cookies, please see our Privacy Policy.
Your access to, and use of, our website is subject to our Terms of Use and all applicable laws and regulations. By accessing and using our website, you accept these Terms of Use. To learn more about the Terms of Use, please visit Terms of Use.
ⓒ 2020-2023 Sana Biotechnology. All rights reserved.